UW Directories | Calendar | Map | MyUW
UW logo
Skip to Main
Human Subjects Division (HSD)

Regulatory Updates

FDA: Draft Guidance: Guidance for Industry and Investigators Safety Reporting Requirements for INDs and BA/BE Studies

Sep 29, 2010 at 7:32am

This document provides guidance to sponsors and investigators on safety reporting requirements for human drug and biological products that are being investigated under an investigational new drug application (IND) and for drugs that are the subjects of bioavailability (BA) and bioequivalence (BE) studies that are exempt from the IND requirements. This guidance contains definitions used for safety reporting, makes recommendations on when and how to submit a safety report, and provides advice on other safety reporting issues that have generated questions from sponsors and investigators.

FDA's guidance documents, including this guidance, do not establish legally enforceable responsibilities. Instead, guidances describe the Agency's current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word should in Agency guidances means that something is suggested or recommended, but not required.

See: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM227351.pdf